The cytokine tumor necrosis factor alpha (TNF-a) is important in generating an immune response against a hepatitis C virus (HCV) infection. The functions of TNF-a may be altered by single-nucleotide polymorphisms (SNPs) in its gene, TNF. We hypothesized that SNPs in TNF may be important in determining the outcome of an HCV infection. To test this hypothesis, we typed nine TNF SNPs in a cohort of individuals with well-defined HCV outcomes. Three of these SNPs were typed in a second cohort. Data were analyzed using logistic regression stratifying by ethnicity, since rates of HCV clearance differ in black subjects versus white subjects. The SNP À863A was associated with viral clearance in black subjects (odds ratios (OR) 0.52, 95% confidence interval (CI) 0.29-0.93). Furthermore, the common wild-type haplotype À863C/À308G was associated with viral persistence in black subjects (OR 1.91, 95% CI 1.24-2.95). These findings were independent of linkage with human leukocyte antigen (HLA) alleles. Further study of this polymorphism and haplotype is needed to understand these associations and the role of TNF-a in determining outcomes of HCV infection.
Introduction
Hepatitis C virus (HCV) is eliminated from the host in approximately 15% of acutely infected individuals (viral clearance). 1, 2 Studies suggest that host immune response differences determine viral clearance. A broad, vigorous cytotoxic T lymphocyte (CTL) response correlated with viral clearance in a study of six chimpanzees. 3 Similarly, studies in humans have shown that a strong, polyclonal CTL response is associated with viral clearance. 4 It is plausible that the vigor of the immune response is determined, at least in part, by host genetic factors. This hypothesis is supported by several immunogenetic studies demonstrating the importance of human leukocyte antigen (HLA) variation with the outcome of an HCV infection. [5] [6] [7] Tumor necrosis factor-alpha (TNF-a) is a cytokine critical for determining the immune response and is produced by a variety of cells, especially activated macrophages. 8 TNF-a is important for a number of Tcell-dependent immune processes including polarization to a Th1 response, induction of apoptosis, and regulation of proliferation. TNF-a has been implicated as an important cytokine in HCV infection since CTLs in the liver secrete TNF-a, 9 elevated serum and liver TNF-a levels are found in persons with chronic hepatitis C, 10 and viral hepatitis infection induces TNF-a production in human hepatocytes. 11 Nonresponse of chronic hepatitis C to interferon-a therapy has been associated with higher pretreatment TNF-a levels. 12 The TNF-a gene, TNF, is located on chromosome 6 in the class III region of the major histocompatability complex between HLA-B and HLA-DR. Several singlenucleotide polymorphisms (SNPs) have been described with the majority being located in the promoter. Three of the promoter SNPs at À863, À308, and À238 have been studied in HCV infection. The SNP À863C/C has been associated with viral persistence, 13 and the SNPs at À238 and À308 have had inconsistent associations with various HCV outcomes. [14] [15] [16] No association has been found between TNF SNPs and response to HCV treatment thus far. 17, 18 The variability in these data may be due to the small size of these studies, examination of only a few of the known SNPs, and/or the different outcomes examined.
Since TNF-a is an important cytokine for the immune response, we hypothesized that SNPs in TNF play a role in natural clearance or persistence of HCV infection. To test this hypothesis, we comprehensively examined TNF by genotyping all known SNPs with a frequency 45% in two large cohorts of individuals with well-defined outcomes of HCV clearance or persistence.
Results

Study subjects
The AIDS Link to Intravenous Experience (ALIVE) cohort, which was primarily black individuals (88%), consisted of 89 persons with viral clearance matched to 176 persons persistently infected with HCV (Table 1 ). In the Multicenter Hemophilia Cohort Study (MHCS), the number of persons was 101 and 191 in the viral recovery and persistently infected groups, respectively. The matching characteristics, HIV status and gender, were similar between those with HCV clearance and persistence in the ALIVE cohort or when the combined cohort was stratified by ethnicity. The mean age was also similar between those with HCV clearance and persistence. As expected, the presence of hepatitis B surface antigen (HBsAg) was more common in those with HCV clearance (Po0.05 in all groups).
Individual SNPs examined in ALIVE and combined cohorts All of the SNPs tested were in Hardy-Weinberg equilibrium. Of the nine SNPs studied in ALIVE, none were significantly associated with viral clearance or persistence in univariate analysis (P40.05), but there was a marginally significant association between À863A and viral clearance (odds ratios (OR) 0.50, P ¼ 0.06) ( Table 2 ). Thus, the only SNPs tested in the MHCS were those that had a higher pretest probability of being associated according to our methods (À238, À308, and À863). None of these were significantly associated with HCV persistence in the MHCS cohort.
Since the association with À863A was seen only in ALIVE, which is predominantly black, and not in the predominantly white MHCS cohort, we hypothesized that the association may be present in black subjects only. Thus, we stratified the combined cohort by ethnicity and found that À863A was significantly associated with viral clearance in black individuals (OR 0.52, 95% confidence interval (CI) 0.29-0.93, P ¼ 0.03) but not in white individuals (OR 1.44, P ¼ 0.20) ( Table 3 ). The association of À863A in black population was a dominant one since having either one or two copies of À863A had a similar association with viral clearance (OR À863A: 0.46; OR À863A/A: 0.50).
To test the hypothesis that this association is independent of known associations in HLA-DRB1 and HLA-B, the two genes closest to TNF, we constructed multivariate models using previously described HLA associations in this cohort. 5, 6 Adjusting for HLA-DRB1*0301, which is associated with HCV persistence, did not change the association of À863A in black population (OR 0.49, P ¼ 0.04). Likewise, adjustment for either HLA-DRB1*0101 or HLA-B*57, which are associated with viral clearance, did not alter the À863A association in black population (OR 0.49, P ¼ 0.04 and OR 0.46, P ¼ 0.02, respectively). In addition, stratification by HIV status did not significantly alter the odds ratio (OR 0.37 and 0.64 for HIV positives and negatives, respectively). Likewise, including HBsAg into a model with À863A did not alter the odds ratio (OR 0.51).
Haplotype analysis
Only the haplotype of À863 and À308 met our criteria for haplotype analysis in black individuals. These SNPs were tightly linked in black individuals (D 0 ¼ 1), and À308A was weakly associated with viral clearance among black population (OR 0.62, P ¼ 0.10, Table 3 ). The À863A variant only occurred with the wild-type G allele at position À308; thus, further haplotype analysis with À863A was not performed. However, the wild-type À863C was found with both the variant and wild-type alleles at À308. The wild-type haplotype À863C/À308G was significantly associated with viral persistence in black individuals (OR 1.94, 95% CI 1.24-2.95, P ¼ 0.003, Table 4 ). Homozygosity for this wild-type haplotype did not substantially strengthen the association (OR 2.29, 95% CI 1.33-3.94, P ¼ 0.003). In contrast, those with a variant allele at either position (À863A or À308A) were more likely to have viral clearance (Table 4) .
Haplotypes were determined between the TNF alleles genotyped in the combined cohort and the HLA-DRB1 and -B alleles previously associated with HCV clearance. 5, 6 Only the DRB1*0301/À308A haplotype in white TNF-a polymorphisms and hepatitis C CL Thio et al subjects met our criteria for analysis with a frequency of 7.8%. This haplotype tended toward an association with viral clearance, but this was not statistically significant (OR 2.0, P ¼ 0.11). There were no haplotypes between the HLA-DRB1 or -B alleles and the SNP at À863.
Discussion
This is the largest, most complete published study to date of TNF SNPs and natural clearance of HCV infection. We found that black subjects, who had at least one copy of the mutant SNP À863A, had half the risk of viral persistence, a finding not detected in white subjects. Haplotype analysis with the SNP at À308 revealed that À863A was only present with the wild-type allele, À308G. Thus, it is difficult to determine precisely whether the association was due to À863A or À308G. However, since À308G was not significant in univariate analysis, it seems most likely that the SNP at À863 was driving the association. The association was independent of HLA since it was not affected by including HLA alleles previously associated with HCV clearance in multivariate models, and since À863 was not linked to any HLA-DRB1 or -B alleles. This study expands on the existing literature with regard to TNF and HCV. The only other study to examine the SNP at À863 evaluated 18 Sicilian patients with HCV clearance and 42 with persistent HCV infection. This study also found À863A to be associated with HCV clearance. 13 The TNF gene has been examined in many other diseases, and À863A has been associated with diseases related to increased immune activation including Crohn's disease 19 and human T-cell lymphotrophic virus-1 uveitis. 20 Other studies of HCV have not noted this association, but most were small and did not examine the SNP at À863. One previous study compared the SNPs at À308 and À238 in 57 individuals with HCV clearance to 93 with persistence, detecting no difference in the distribution of these SNPs.
14 Likewise, another study did not find the SNP at À308 to be associated with viral recovery or persistence.
21 À308A has been associated with increased cirrhosis in HCV-infected patients, 16 whereas À238A was Total number of black and white alleles assessed is two times the number of people in Table 1 .
TNF-a polymorphisms and hepatitis C CL Thio et al more frequent in HCV-infected individuals compared to uninfected controls. 15 Studies of TNF polymorphisms and clearance of HCV in response to interferon-a therapy have also not studied the SNP at À863. [21] [22] [23] Given the findings in this study, it would be interesting to examine this polymorphism with respect to outcomes after treatment of chronic hepatitis C, which may facilitate a comparison between immune mechanisms involved in clearance either naturally or with therapy.
Functional studies of the individual promoter SNPs at À863 and À308 have been inconsistent but indicate that these positions likely influence the production of TNF-a, which may in turn affect the outcome of an HCV infection. Comparison of the À863A allele to the À863C has linked À863A to a spectrum of effects including reduced circulating levels of TNF-a, 24 increased TNF-a production by stimulated PBMCs, 25 and no effect on TNF-a gene expression. 26 These disparate results suggest that the net effect of variants in the promoter region varies according to which of the multiple transcription factors binds to it. The ubiquitous transcription factor OCT-1 has increased binding to the TNF promoter in the presence of the À863A allele. 27 There is also differential binding of the transcription factor NF-kB to the TNF promoter based on the allele at À863. The effects of À863A are dependent on the proportion of the p65 and p50 NF-kB subunits present, which varies with the cell type and its activation factors. 28, 29 In vivo, it is unclear how the interplay of these various transcription factors and variables would ultimately affect the complex process of TNF expression.
Similarly, functional studies of the allele À308A have been inconsistent, with both higher 30 and no change 31, 32 in TNF-a production in cells stimulated with lipopolysaccharide. Studies using gene reporter assays have also shown effects ranging from increased 33 to no change 26, 34 in gene transcription. Since these studies use different approaches, it is difficult to compare them to determine the effect of À308A on TNF-a production. It is not clear why the association with À863A was only present in black individuals, but since clearance rates differ by ethnic groups, 35 this finding was not surprising. Given the complex interactions with various transcription factors and the TNF promoter discussed above, it is possible that the interactions with the SNPs differ between ethnic groups. Different patterns of linkage disequilibrium between ethnic groups occur and may also explain the results. It is possible that this SNP and haplotype are in linkage disequilibrium with another gene or unidentified TNF SNP that is actually responsible for this association. Linkage with the HLA genes did not appear to account for the findings, but many other genes are in proximity to TNF. Epistatic interactions between this haplotype and TNF-a receptor polymorphisms, which may differ by ethnicity, could account for our findings. Lastly, it should also be noted that the upper tail of the confidence interval in black individuals and the lower tail in white individuals overlap slightly; thus, it is possible that the association exists in white individuals but was not detected in this population.
Approximately half of our subjects were HIV infected, but this should not have affected the results of our study for several reasons. First, HCV infection usually occurs within the first 2 years of using injection drugs, which is generally prior to HIV infection. 36, 37 The same is true of hemophiliacs because clotting factor concentrates were derived from more than 10 000 donors and nearly always transmitted HCV on the initial dose, so they are almost certain to have been infected with HCV prior to HIV. Furthermore, since HCV clearance or persistence is determined in the first 6 months to 1 year after the acute infection, 2 the outcome of the HCV infection is determined prior to HIV infection. Second, those with viral recovery and persistence are matched on HIV status. Third, stratification of the analysis by HIV status did not significantly alter the results.
A limitation to this study is that the black subjects form a potentially genetically heterogeneous group since several racial subcategories can be included. We tried to minimize this bias as much as possible by matching based on subcategories of blacks and by placing the hispanic blacks in the other category for analysis. However, we acknowledge that genetic heterogeneity may still exist in the black population, which could bias the results.
In summary, we found that the mutant allele À863A is associated with HCV clearance in black individuals and that the common wild-type haplotype À863C/À308G is associated with HCV persistence in black individuals. Thus, genetically determined polymorphisms in TNF have a role in determining the outcome of an HCV infection. Functional studies of this SNP and haplotype may help us understand the effects of TNF-a during an acute HCV infection.
Methods
Study participants
Subjects in this study were participants in one of two studies: (i) ALIVE study, an ongoing study of 2921 injection drug users enrolled in Baltimore, MD, from February 1988 to March 1989, as described previously, 38 or (ii) MHCS, a prospectively followed cohort of patients To investigate the hypothesis that TNF SNPs might be associated with recovery from hepatitis C, a nested casecontrol design was used in which one person with viral clearance (case) was matched to two persons from the same cohort with viral persistence (controls) but were otherwise similar with regard to nongenetic factors. The matching criteria were HIV status, gender, geographic location, and ethnicity. 35 Prior infection was substantiated by detection of HCV antibody (anti-HCV) by enzyme immunoassay (EIA) and recombinant immunoblot assay (RIBA). Individuals with HCV recovery had anti-HCV (confirmed by RIBA) and undetectable HCV RNA in the serum for a minimum of 6 months. Persistently infected individuals had detectable anti-HCV and HCV RNA in serum for a minimum of 6 months.
Informed consent was obtained from all participants and the study was approved by the institutional review boards at all participating institutions.
Serologic testing
Subjects who tested positive for anti-HCV by second generation Ortho HCV 2.0 EIA (Ortho Diagnostic Systems, Raritan, NJ, USA) had two samples, separated by a minimum of 6 months, assessed for HCV RNA by a branched DNA (bDNA) assay (Quantiplex HCV RNA 2.0 assay, Chiron Corporation, Emeryville, CA, USA). Subjects with two samples below the limit of detection by bDNA had at least one of those samples retested with the HCV COBAS AMPLICOR system (COBAS AMPLICOR HCV, Roche Diagnostics, Branchburg, NJ, USA; lower limit of detection 50 IU/ml) and their antibody status confirmed by a RIBA (RIBA 3.0) (Chiron Corporation, Emeryville, CA, USA). Only subjects with a negative HCV RNA confirmed by COBAS were defined as viral clearance. Subjects with two positive bDNA assays were defined as having a persistent HCV infection.
HIV-1 testing was carried out by EIA and positive specimens were confirmed by Western blot as reported previously. [38] [39] [40] HBsAg status was determined by EIA (AUSZYME; Abbott Laboratories, Abbott Park, IL, USA). All assays were performed according to the manufacturer's specifications with the exception of COBAS testing in samples that contained heparin. These samples were treated with heparinase prior to COBAS using a Roche protocol for sample preparation of heparinized plasma. All samples used for testing had been stored at À701C after processing and had not been previously used for other assays.
DNA extraction and TNF genotyping Epstein-Barr virus transformed cell lines were established for each individual. Genomic DNA was extracted from these cell lines using phenol-chloroform extraction. The following previously identified SNPs with a published frequency of Z5% in at least one report were typed in the ALIVE cohort (the minus sign indicates the SNP is located in the promoter region): À1073, À1031, À863, À376, À308, À244, À238, þ 851, and þ 1304 41 (http://pga.gs.washington.edu/). A frequency of 5% was chosen in order to minimize the number of comparisons with limited power. These biallelic SNPs were genotyped using a PCR-sequence-specific primer (SSP) protocol and primers adapted from Richardson et al, 41 in which two complementary reactions are run for each SNP. The two reactions share a common primer, but the second primers differ at their 3 0 -terminal ends by one base, which represent the bases at the polymorphic alleles. The PCR products were run on a 1% agarose gel and an allele was assigned as present if a band was detected. The procedure was verified by sequencing 10 individuals at each SNP with no errors. Ambiguous genotypes from the SSP were assigned based on sequencing.
Testing strategy and statistical analysis All the SNPs were initially genotyped in the ALIVE cohort. Hardy-Weinberg equilibrium was assessed by the w 2 test with one degree of freedom. Based on the genotypes of the subjects, the allele frequency of each SNP was calculated in those with viral persistence and recovery. OR, which reflect the likelihood of carrying a specific allele if persistently HCV infected, 95% CI, and P-values were calculated using conditional logistic regression using SAS (SAS Institute, version 10, Cary, NC, USA). Since À238, À308, and À863 have previously been associated with various HCV outcomes, each of these SNPs along with any SNP with a Po0.10 in ALIVE were genotyped in the MHCS participants to confirm findings. A Po0.10 was chosen in order not to exclude prematurely any suggestive markers. We used PHASE v.2.0.2 42 (http://www.stat.washington.edu/stephens/ phase.html) to construct two-locus haplotypes between any SNP with a Po0.05 and linked SNPs that had a mutant allele frequency of 45%.
Since HCV clearance is associated with being HBsAg seropositive, we constructed a multivariate model with HBsAg and any marker with a confirmed Po0.05 to determine whether the association was independent of HBsAg status. All significant results were also stratified by HIV status.
Linkage disequilibrium was determined between the TNF alleles typed in the combined cohort and previously determined HLA-B and HLA-DRB1 alleles, 5, 6 the two loci closest to TNF, using Arlequin (http://lgb.unige.ch/ arlequin/). HLA-TNF haplotypes in which the haplotype including the mutant TNF allele had a frequency 45% were compared between those with viral clearance and persistence using conditional logistic regression to calculate OR and P-values.
